{"id":"W4410264696","doi":"10.1016/j.jhep.2025.04.025","title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial","year":2025,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Alberta; William Osler Health System","funders":"Ipsen; Astellas Pharma; NGM Biopharmaceuticals; Ipsen Biopharmaceuticals; Gilead Sciences; Novo Nordisk; Eisai; Sanofi; Dr. Falk Pharma; GlaxoSmithKline; AstraZeneca","keywords":"Primary sclerosing cholangitis; Randomized controlled trial; Medicine; Internal medicine; Gastroenterology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002587261,0.001261093,0.002758153,0.0003345748,0.0004956151,0.00103702,0.0005826012,0.001849641,0.008762112],"category_scores_gemma":[0.002788711,0.0004244227,0.001642447,0.0002990142,0.0009175031,0.0009687325,0.0004168252,0.001613623,0.0008707432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006150608,"about_ca_system_score_gemma":0.001057446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005722601,"about_ca_topic_score_gemma":0.001195778,"domain_scores_codex":[0.998917,0.0006417933,0.00008274759,0.0001582864,0.00007523225,0.0001248766],"domain_scores_gemma":[0.998924,0.0002798315,0.0003197169,0.0000754276,0.0001183465,0.0002826331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9819378,0.002370852,0.0007785495,0.0009233766,0.000959745,0.00004683104,0.00003399208,0.0001168085,0.00103111,0.0001335864,0.001031075,0.01063628],"study_design_scores_gemma":[0.9837794,0.01390852,0.001013961,0.00004785845,0.0003317392,0.00003075213,0.00001287315,0.0001437645,0.0001263771,0.0000960825,0.0005018903,0.000006735765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9614262,0.01712565,0.001534091,0.002891179,0.00118893,0.007961158,0.002721418,0.0002596672,0.004891717],"genre_scores_gemma":[0.9737926,0.00467826,0.002484103,0.003122747,0.000859584,0.009236944,0.001784965,0.00003103278,0.004009666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008762112,"threshold_uncertainty_score":0.02931219,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01007799212067643,"score_gpt":0.2877894008974864,"score_spread":0.2777114087768099,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}